A Strategic Acquisition to Enhance Hemostasis Diagnostic Solutions

A Strategic Move in Hemostasis Diagnostics

In a remarkable development in the medical diagnostics field, Precision BioLogic Inc. has announced its acquisition of George King Bio-Medical, a firm that specializes in diagnostic products for hemostasis. This strategic partnership is set to leverage the synergies between the two companies to enhance products tailored for individuals with coagulation disorders.

A Shared Vision for Innovation

Paul Empey, the CEO of Precision BioLogic, expressed enthusiasm about this acquisition, stating, "Since its founding over 50 years ago, George King Bio-Medical has stayed true to its mission of helping those who suffer from bleeding disorders. Our organizations share a similar goal. Together, we can continue to work with our existing clients and partners while exploring new opportunities to assist others in the coagulation community."

This acquisition not only reflects a robust commitment to improve patient care but also aligns with Precision BioLogic’s vision of advancing diagnostic solutions.

The Legacy of George King Bio-Medical

Founded in 1973 by George J. King, George King Bio-Medical has developed a reputation for quality and dedication to service. The company's focus on providing fresh frozen human plasmas has set high standards in the clinical lab environment. The CEO of George King Bio-Medical, Kathryn Blasco, who is also the founder’s daughter, commented, "By joining forces with Precision BioLogic, we continue our tradition of compassion and innovation. The future looks promising for us and our clients."

The commitment of George King Bio-Medical to maintain its high-quality products and outstanding service will continue, focusing on customer relationships and the ongoing development of new solutions.

Enhancing Product Offerings

Precision BioLogic's acquisition aims to strengthen its position in the coagulation disorder diagnostics market, already known for its impressive CRYOcheck™ product line. The addition of George King Bio-Medical signifies an expansion of its clinical offerings. With the recent acquisition of Affinity Biologicals in 2018, Precision BioLogic has continuously worked to broaden its array of products related to coagulation and beyond.

The integration of George King Bio-Medical’s reputable services and products should create comprehensive diagnostic capabilities, making impactful contributions to laboratories worldwide. Clients can anticipate not only a seamless transition but also potential access to enhanced services and innovative product developments.

Future Developments

Under the leadership of Precision BioLogic, both companies will continue their regular operations while formulating long-term strategic plans. This commitment to not only sustain but also enhance the level of service provided represents a forward-thinking approach to the challenges faced in the diagnostics world.

In conclusion, the acquisition of George King Bio-Medical by Precision BioLogic illustrates a significant step towards ensuring that patients suffering from coagulation disorders receive improved diagnostic solutions. With a shared focus on quality, innovation, and customer care, this partnership symbolizes a promising future for both organizations and those they serve.

For more information about both companies, visit Precision BioLogic and George King Bio-Medical.